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Abstract
Background:  The novel cytokine, interleukin (IL)-18, is a strong interferon-γ inducer and
costimulatory factor in Th1 cell activation. IL-18 triggers IFN-γ production and enhances cytolytic
activity in both T and NK cells. However, the exact mechanism of antitumor action of IL-18 remains
to be clarified. To determine the effects of IL-18 plasmid DNA on hepatic cancer in mice, CT26
murine colon adenocarcinoma cells were established in mouse liver.
Methods: Plasmid vectors encoding IL-18 were transferred directly into the liver 7 days after
tumor injection to restrict IL-18 expression within the tumor site. The IL-18 protein level was
increased in the liver 4 days after plasmid injection, and a marked antitumoral effect was observed
at day 7. Antitumor effects were evaluated by measuring tumor regression, immune cell population,
and IFN-γ production.
Results: The IL-18 plasmid controlled the growth of hepatic tumors and proliferation of splenic
immune cells. Moreover, treatment of CT26 tumors with the IL-18 plasmid significantly enhanced
the population of the effector T and NK cells in the spleen and peripheral blood. In spleen, the
population of CD4+CD62Low cells was augmented in response to IL-18 on day 7. These results are
consistent with the increase in CD4+ T cells secreting IFN-γ, but not CD8+ T cells. The marked
reduction of tumor growth in tumor-bearing mice was associated with the maintenance of IFN-γ
production in spleen in response to IL-18. These antitumoral effects were maintained until 14 days
after plasmid injection.
Conclusion: Our results suggest that direct plasmid DNA transfer of IL-18 with no accompanying
reagents to augment transfection efficiency may be useful in tumor immunotherapy.
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Background
Effective eradication of established tumors and generation
of a lasting systemic immune response with a simple gene
delivery system are important goals for cancer gene immu-
notherapy [1]. Cytokines are the most extensively studied
immunostimulatory agents in cancer gene therapy [2].
Interferon-γ-inducing factor (IL-18) is a recently character-
ized murine and human cytokine. The murine IL-18 gene
encodes a precursor protein of 192 amino acids, which is
processed to a mature protein containing 157 residues [3].
This cytokine, produced by Kupffer cells, is a potent
inducer of IFN-γ production by T cells and a costimulatory
factor for T cell activation [4,5]. Accumulating evidence
that IL-18 is a multifunctional cytokine that shares several
biological activities with IL-12 has led to a series of studies
on its effects on T and NK cells [4]. Analogous to IL-12, IL-
18 stimulates T cell proliferation and NK cell activity [3].
The finding that IL-18 stimulates the differentiation of
Th1 cells that produce cytokines necessary for the devel-
opment of cell-mediated immune responses suggests a
prominent role in defense against tumors [6]. Similarly,
high IFN-γ levels are induced by IL-18 in splenic-derived
CD4 T cells in the presence of B cells or adherent cells [7].
Furthermore, IL-18-transfected tumor cell vaccines and
local delivery of the IL-18 gene as naked DNA via a gene
gun or viral vectors has been extensively investigated.
Numerous animal studies show that IL-18 has potent
antitumor effects, but induces side-effects upon systemic
administration [8]. Direct intratumoral DNA administra-
tion is reliable and reproducible, and may limit the need
for systemic cytokine administration [9-11]. Here, we
report the effects of direct intratumoral injection of a non-
viral plasmid vector encoding murine IL-18 DNA in estab-
lished CT26 liver tumors [12].
Methods
Animals and cell lines
BALB/c (H-2d) mice (6 to 8 weeks old) were obtained
from the Jackson Laboratory (Bar Harbor, ME, USA). All
mice were housed in specific pathogen-free conditions, in
accordance with institutional guidelines. CT26 tumor
cells were maintained in RPMI 1640 cell culture medium
(Biowhittaker, Walkersville, MD, USA) supplemented
with 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 100 U/ml streptomycin, and 100 μg/ml peni-
cillin.
Plasmids
The 11 kb mIL-18 DNA expression plasmid vector,
pCEP4-mIL18, was constructed using a CMV early
enhancer/promoter/EBNA-1-based pCEP4 plasmid vector
(Invitrogen, San Diego, CA) with an ampicillin selection
gene. Plasmid DNA was purified in the absence of ethid-
ium bromide using a commercial column chromatogra-
phy method, according to the manufacturer's protocol
(Qiagen, Chatsworth, CA).
Tumor model and therapeutic protocol
CT26, an undifferentiated murine adenocarcinoma, was
induced by rectal injection of N-nitroso-N-methyl-
urethane in BALB/c mice. Colorectal cancer is often meta-
static, the most common site of metastasis being the liver.
CT26 cells were suspended for implantation at 1 × 105
cells/50 μl saline. Colon carcinoma was established in the
left lateral lobe of 6- to 8-week-old male BALB/c mice by
an abdominal operation. Treatments began 7 days after a
defined solid tumor growth was identified within the
injected lobe. For intratumoral injection, naked DNA (10,
25, and 50 μg) was diluted in 50 μl saline, and injected
into the parenchyma of the lower surface of the left liver
lobe via insulin syringes (31 gauge, 0.8 inch needles; Bec-
ton Dickinson, Franklin Lake, NJ). Mice were sacrificed at
1, 4, 7, and 14 days after DNA treatment, and tumor
growth monitored by measuring liver weight [13].
Flow cytometric analysis
Total nuclear cells in the peripheral blood were isolated
by erythrocyte lysis with ammonium chloride solution
(PharM Lyse, Becton Dickinson). Single spleen cell sus-
pensions were obtained by teasing apart spleen tissue and
disaggregating cells through a 70 μm mesh. Briefly, splen-
ocytes and PBMCs were incubated with PE-, Cy5, or FITC-
conjugated Abs, and the corresponding isotypes (pur-
chased from Pharmingen, San Diego, CA, USA). Anti-
mouse NK (clone DX5), -CD3, -CD4, -CD8, -Cd62L, -
CD69, -CD19, and -CD11b Abs were used to stain the
populations of NK cells, macrophages, T-cells, and B-cells
in the spleen. Samples were analyzed for surface pheno-
types using FACS Vantage (Becton-Dickinson, San Jose,
CA, USA) and CellQuest software (Becton-Dickinson
Labware).
Flow cytometric assessment of intracellular cytokine 
production
For parallel evaluation of intracellular cytokines, surface
staining was initially performed for CT26 lysate-stimu-
lated splenocytes from each group. Cells were fixed with
4% paraformaldehyde solution for 20 min, treated with
permeabilization buffer (0.1% saponin, 1% FBS in PBS)
for 5 min at RT in the dark, and washed. Intracellular
staining was performed by incubation of mAb to IFN-γ
with cell pellets for 20 min at RT in the dark. Cells were
washed, and measured using a flow cytometer.
Assessment of cytokines (IL-18, IFN-γ)
We obtained total liver protein by homogenization of fro-
zen tissue in extraction buffer containing 1% Triton X-
100, 10 mM Tris-HCL (pH 7.6), 5 mM EDTA, 50 mM
NaCl, 30 mM Na4P2O7, 50 mM NaF, 200 μM Na3VO4, 2BMC Cancer 2007, 7:87 http://www.biomedcentral.com/1471-2407/7/87
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mM PMSF, 5 μg/ml aprotinin, 1 μg/ml pepstatin A, and 2
μg of leupeptin. The suspension was centrifuged at 14,000
r.p.m. for 20 min at 4°, and the supernatant stored at -
70°. Supernatant fractions were analyzed with the IL-18
ELISA kit (MBL, Nagoya, Japan). IFN-γ concentrations in
the splenocyte culture supernatants were determined with
specific ELISA performed according to the manufacturer's
instructions (R&D Systems, Minneapolis, MN, USA). The
absolute cytokine levels were calculated by comparison to
assay performance in the presence of known quantities of
recombinant cytokine standards.
Statistical Analysis
An unpaired t-test was employed to compare tumor
weight, quantitative cytokine production, and flow
cytometry analyses. All analyses were performed with Sig-
maPlot 2000. P < 0.05 was considered significant.
Results
Levels of transgene expression within the treated tumor 
site
To determine the efficiency of gene transfection, mouse
IL-18 protein expression in the tumor site was evaluated
by ELISA. mIL-18 protein was detected in all samples
injected with control vector or IL-18 plasmid (Figure 1).
However, significant differences were evident in the mIL-
18 protein levels between the control and the 50 μg plas-
mid-injected group. Protein levels in CT26 treated with
control or mIL-18 plasmid vector ranged from 500 to 900
mg in the injected lobe, since tumors developed differen-
tially after each treatment. The IL-18 protein level was 2–
2.5 fold higher than background when mice were sacri-
ficed 4 days after plasmid introduction. The results suggest
that mIL-18 DNA is expressed in the tumor site, and
releases bioactive IL-18.
In vivo kinetic studies of the immune cell population in 
spleen
We performed phenotype analysis of spleen cells from
pCEP4, mIL-18 DNA-treated CT26 tumor-bearing mice
on days 2, 5, and 7 after gene treatment, using flow cytom-
etry. The antitumoral response of tumor-bearing mice
treated with 50 μg of DNA was significantly greater than
that of mice administered 10 or 25 μg DNA. Intratumoral
delivery of 50 μg of plasmid DNA for each of four treat-
ments resulted in immune cell augmentation in CD4+
cells (30.6% total lymphocytes versus 15% in control),
CD8+ cells (13.5% total lymphocytes versus 6% in con-
trol), and NK cells (5.6% total lymphocytes versus 3.5%
in control) on day 7 (Figure 2). Other groups report that
IL-18 upregulates ICAM-1 expression on monocytes and T
cells, presenting further evidence of IL-18-stimulated T
cell recruitment [14-17]. These findings, together with the
above kinetic data on the immune cell populations, sug-
gest that a ~ 2.5-fold higher concentration of IL-18 mod-
ulates the immune cell population (T cells and NK cells)
around the time of tumor regression.
Regression of established CT26 hepatic tumors after direct 
intratumoral mIL-18 gene transfer
CT26-tumor bearing mice were treated with 50 μg pCEP4
or mIL-18-pCEP4, and tumor growth measured at the
indicated times (Figure 3). Tumor growth was signifi-
cantly lower in the groups treated with mIL-18 plasmid
than those administered control vector (pCEP4). Most of
the control mice developed multiple large tumors in the
liver, but pIL-18 gene therapy markedly inhibited tumor
growth at 14 days and 21 days after tumor implantation
(see additional file 1). Differences between the control
and mIL-18-treated groups were statistically significant (p
< 0.049 on day 14), as confirmed with the Student's t test.
Regression phenotypic changes of immune effector cells in 
spleen and blood samples
Changes in cell surface activation markers define specific
phases of T cell activation, and may be used to distinguish
between naïve, effector, and memory T cell populations
[18]. Resting naïve T cells express low levels of CD44 and
integrins, LFA-1 and VLA-4, and high levels of CD45RB
and CD62L (L-selectin). Upon antigen stimulation, naïve
T cells transform into large blastoid cells, and the pheno-
types of these effector cells become CD44hiLFA-1hiVLA-
Detection of mIL-18 plasmid expression in DNA treatment  sites Figure 1
Detection of mIL-18 plasmid expression in DNA 
treatment sites. BALB/c mice were inoculated with murine 
CT26 cells in the left liver lobe, and treated intratumorally 
with varying doses of control plasmid or that expressing IL-
18 until day 7 after tumor inoculation. Liver tissue was 
obtained on day 4 after direct injection of IL-18 plasmid 
DNA, and ELISA used to evaluate IL-18 protein levels. Rep-
resentative data determined from two separate experiments.BMC Cancer 2007, 7:87 http://www.biomedcentral.com/1471-2407/7/87
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4hiCD45RBloCD62L-[18,19]. Other activation markers,
such as CD25 and CD69, are additionally upregulated
[20,21]. Accordingly, flow cytometric analysis of spleen
and blood cells from pCEP4 or mIL-18 plasmid-treated
CT26 tumor-bearing mice at 7 days after gene treatment
was performed. As expected (Table 1), a marked increase
(p  < 0.04) in the CD4+CD62Low subset was evident in
spleen and blood cells following injection of mIL-18 plas-
mid DNA (30.05 ± 1.85% in spleen and 30.58 ± 4.59% in
blood), compared with the pCEP4 DNA-treated control
group (17.75 ± 0.92% in spleen and 17.62 ± 2.15% in
blood).
IL-18 induces IFN-γ production in T cells [5,7,22]. To fur-
ther characterize the mIL-18- induced immune response,
intracellular cytokine staining for IFN-γ production was
performed for subsets of CT26-specific T cells. Splenocytes
were prepared and pooled from CT26 tumor-bearing mice
treated with pCEP4 or mIL-18 plasmid incubated with
medium alone or supplemented with CT26 lysates. The
frequencies of functional CT26-specific T lymphocytes
were estimated by intracellular IFN-γ staining, and quan-
titation of activated CD69+, IFN-γ+, CD4+, and CD8+ cells
(Figure 4). While control mice treated with pCEP4 did not
generate a CT26-specific T cell response, those adminis-
tered pmIL-18 contained a significant number of IFN-γ
producing CD4+ T cells, but not CD8+ T cells (data not
shown). The data suggest that the IL-18-mediated
immune response predominantly involves IFN-γ-produc-
ing CD4+ T cells.
IL-18 gene transfer results in regression of CT26 liver  tumors Figure 3
IL-18 gene transfer results in regression of CT26 liver 
tumors. CT26 cells (1.0 × 105) were injected into a left lobe 
of the livers of 6-8-week-old BALB/c mice. pCEP4 or mIL-18 
plasmid DNA was injected directly into the tumors on day 7. 
Tumor growth was measured on days 1, 4, 7, and 14 after 
plasmid implantation. Data are presented as the mean of 
tumor weights of 8 mice/group.
Immune response is enhanced by a single injection of naked  IL-18 plasmid DNA Figure 2
Immune response is enhanced by a single injection of 
naked IL-18 plasmid DNA. Each group (consisting of 4 
mice) was administered an intratumoral injection of pCEP4 
or naked mIL-18 DNA. Spleens of CT26 tumor-bearing mice 
treated with plasmids were harvested at 7 days after plasmid 
injection, and cells analyzed by flow cytometry using the cor-
responding FITC- or PE- or PE-Cy5-labeled antibodies and 
isotype control.BMC Cancer 2007, 7:87 http://www.biomedcentral.com/1471-2407/7/87
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DNA vaccination of mice resulted in broad immune
responses, characterized by the activation of B cells, helper
CD4+ and cytotoxic CD8+ T cells [23]. Based on these
results, we propose that mIL-18 overexpression in the
tumor site induces phenotypic changes in the T cell and B
cell subsets, and protects against tumor development by
stimulating IFN-γ production by CD4+ T cells.
Intratumoral injection of mIL-18 plasmid DNA elevates 
IFN-γ production by splenocytes
The IFN-γ levels of cultured splenocyte supernatants were
compared. Enhanced secretion of IFN-γ by cultured splen-
ocytes was evident in animals treated with plasmid mIL-
18 DNA (1.278 ± 0.06 ng/106 cells/72 h), compared to
splenocytes from mice treated with pCEP4 control vector
(1.026 ± 0.03 ng/106 cells/72 h; P = 0.006). This may
explain the continued maintenance of tumor suppression
in mIL-18-treated mice, compared to control mice (Figure
5). Interestingly, in our studies with tumor-bearing mice,
intratumoral injection with an IL-18 plasmid did not pre-
vent CT26 tumor development, although augmentation
of T cells and maintenance of the IFN-γ level during 2
weeks appeared to reject tumors. Thus, while direct
cytokine gene transfer possibly has therapeutic potential,
expression of cytokine genes may be elevated and sus-
tained significantly during tumor development. Other
reports show that the effects of cotransfection of ICE and
pro-IL-18 cDNA are superior to those of pro-IL-18 cDNA
alone, and result in enhanced bioactivity of IL-18 [24].
Intracellular IFN-γ production by CT26-specific T cells from pmIL-18-treated mice Figure 4
Intracellular IFN-γ production by CT26-specific T cells from pmIL-18-treated mice. Splenocytes from CT26-tumor 
bearing mice treated with three rounds of pCEP4 or mIL-18 were pooled and incubated in medium alone or that containing 
CT26 lysates. Numbers within the gates in the FACS plots depict the percentage of CD69+ IFN-γ+ CD4+ cells. Data are pre-
sented from experiments that were repeated at least twice.
Table 1: Frequency of CD4+CD62Low, CD8+CD62Low, DX5+, CD19+cells in spleen and blood: major subsets
Treatment Group Spleens Blood
CD4+CD62Low (%) CD8+CD62Low (%) DX5+ (%) CD19+ (%) CD4+CD62Low (%) CD8+CD62Low (%) DX5+ (%) CD19+ (%)
pCEP4 17.75 ± 0.92 0.997 ± 0.05 3.39 ± 1.26 44.51 ± 3.40 17.62 ± 2.15 5.93 ± 0.96 15.45 ± 1.19 28.97 ± 3.52
pIL-18 30.05 ± 1.85a 1.995 ± 0.34 1.73 ± 0.08 41.57 ± 1.09 30.58 ± 4.59a 9.88 ± 0.94 18.4 ± 2.91 36.49 ± 5.95
Spleen and blood samples of CT26 tumor-bearing mice treated with pCEP4 or mIL-18 plasmid DNA were harvested 7 days after gene treatment, and cells analyzed by flow 
cytometry using the corresponding FITC-, PE-, or PE-Cy5-conjugated antibodies and isotype control. Data are presented as means ± SD of 8 mice/group. a P < 0.04, compared 
with the pCEP4 control-treated group.BMC Cancer 2007, 7:87 http://www.biomedcentral.com/1471-2407/7/87
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Conclusion
Recent trials using cytokine genes show that intratumoral
IL-18 gene transfer is a feasible procedure, but exerts only
mild antitumor effects [24]. Gene transfer with increased
mIL-18 doses may enhance antitumor efficacy. In this
study, we validate the antitumoral efficacy of mIL-18 over-
expression in CT26 tumor-bearing mice by using plasmid
vectors to transfer the mouse IL-18 gene alone. Our data
show marked inhibition of tumor growth and significant
phenotypic changes of immune cells, suggesting that mIL-
18 intratumoral plasmid transfer may be developed as an
effective alternative therapy for cancer treatment with no
significant side-effects.
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